However, it was in 2017 that the first and only bispecific T cell engager (BiTE) antibody, binding CD19 and CD3, was approved for the treatment of patients with relapsed or refractory B-cell precursor acute lymphocytic leukaemia (ALL) [19]. Here, CD19 is linked to acute lymphoblastic leukemia.